Nafarelin

CHEMBL1201309 Phase 4 Đã phê duyệt Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1322.5 g/mol
LogP
0.8
Phase
4

This hormone-based medication is used as a nasal spray to treat endometriosis and precocious puberty by reducing the production of sex hormones. It works by initially stimulating and then suppressing the pituitary gland's release of hormones that control estrogen and testosterone levels.

Khối lượng phân tử

1322,5000 g/mol

LogP

0,80

TPSA

475,00 Ų

Lipinski RO5

Không đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

InChI

InChI=1S/C66H83N17O13/c1-36(2)26-48(58(89)76-47(16-8-24-71-66(68)69)65(96)83-25-9-17-54(83)64(95)73-33-55(67)86)77-60(91)50(28-39-12-7-11-38-10-3-4-13-43(38)39)79-59(90)49(27-37-18-20-42(85)21-19-37)78-63(94)53(34-84)82-61(92)51(29-40-31-72-45-15-6-5-14-44(40)45)80-62(93)52(30-41-32-70-35-74-41)81-57(88)46-22-23-56(87)75-46/h3-7,10-15,18-21,31-32,35-36,46-54,72,84-85H,8-9,16-17,22-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,94)(H,79,90)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1

Molecular Formula

C66H83N17O13

HBD / HBA

16 / 15

Liên kết có thể quay

33

Nguyên tử nặng

96

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This hormone-based medication is used as a nasal spray to treat endometriosis and precocious puberty by reducing the production of sex hormones. It works by initially stimulating and then suppressing the pituitary gland's release of hormones that control estrogen and testosterone levels.

Yes, Nafarelin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201309. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25077405. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.